Remarkable response to dacomitinib in a patient with leptomeningeal carcinomatosis due to EGFR‐mutant non‐small cell lung cancer

Remarkable response to dacomitinib in a patient with leptomeningeal carcinomatosis due to EGFR‐mutant non‐small cell lung cancer

Dacomitinib, a second‐generation epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor, is a standard therapeutic option for patients with EGFR‐mutant non‐small cell lung cancer (NSCLC). However, its efficacy in patients with central nervous system lesions is unclear. Here, we describe a...

Full description

Bibliographic Details
Main Authors: Shun Mizusaki, Kohei Otsubo, Toshifumi Ninomiya, Hidenobu Arimura, Yuko Tsuchiya‐Kawano, Koji Inoue
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Thoracic Cancer
Subjects:
Dacomitinib
EGFR mutation
leptomeningeal carcinomatosis
non‐small cell lung cancer
Online Access:https://doi.org/10.1111/1759-7714.13712

Internet

https://doi.org/10.1111/1759-7714.13712

Similar Items